We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Thyroid hormone receptors
- Thyroid hormones production
- Thyroid hormones regulation
- THRα and THRβ
- THR targeting drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2025, June 30). Thyroid hormone receptors (NR1A): biological role & drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 3, 2025, from https://doi.org/10.69645/RTRG1600.Export Citation (RIS)
Publication History
- Published on June 30, 2025
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Other Talks in the Series: Nuclear Receptors as Common Therapeutic Targets
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome everyone to Chapter 9 of
this short talk series on
nuclear receptors as
therapeutic targets.
Now after the general part on
the features and mechanisms
of nuclear receptors,
we will now look at the
individual subfamilies and
receptors of this family and
at their functions
and their ligands.
0:21
We will go through
the nuclear receptors
systematically, family
by family, and we start
in this Chapter 9 with
the thyroid hormone receptors
which are the NR1A family.
There are two thyroid
hormone receptor isoforms,
THR Alpha and THR Beta.
As the name indicates,
thyroid hormones are
the natural ligands
of the thyroid
hormone receptors.
0:47
They are produced
in the colloid of
the thyroid gland
by iodination of
tyrosine residues in the
protein thyroglobulin,
and after generation of
mono- and diiodotyrosine
residues in thyroglobulin,
two such residues are fused
to the thyroid hormones by
the enzymatic activity
of thyroid peroxidase.
The processed thyroglobulin
is then taken
up into the thyrocytes
and the proteolysis
releases the free thyroid
hormones; levothyroxine
and triiodothyronine
abbreviated as T4 and T3
according to the number of
contained iodine atoms.
1:29
The thyroid hormone
system is regulated
by the thyrotropin-releasing
hormone,
which is released from the
hypothalamus and then stimulates
the pituitary gland to
release the
thyroid-stimulating hormone,
abbreviated as TSH,
and also known as thyrotropin,
which, in turn, then stimulates
the thyroid gland to
produce T4 and T3.
T3 and T4, in turn,
block TRH and TSH release
in the hypothalamus and
the pituitary gland and thus,
regulate their own levels in
a negative feedback mechanism.
T4 and T3 are produced in
the thyroid gland
and released to
the circulation approximately
in a 14-1 ratio.
However, T3 is more active as
hormone and thyroid hormone
receptor agonist, by 3-44.
Therefore, T4 is deiodinated in
the peripheral organs
to T3 by deiodinases,
and further deiodination then
inactivates the hormone.
Three activates the
thyroid hormone receptors,
which form heterodimers
with RXR and
RDNA bound also in the
absence of their ligand.
In absence of T3,
the thyroid hormone receptor,
RXR dimer, recruits
an co-repressor complex and
thus, suppresses
gene expression,
as shown here on
the upper right.
T3 binding induces
the release of
the co-repressor complex
and the recruitment of
a co-activator
complex to activate
expression of thyroid hormone
receptor-regulated genes.
By this mechanism,
thyroid hormones regulate
the metabolism of almost
every tissue in the body.